PL3811949T3 - Lek kombinowany zawierający kompozycję liposomową z kapsułkowaną gemcytabiną i blokadę punktu kontroli immunologicznej - Google Patents

Lek kombinowany zawierający kompozycję liposomową z kapsułkowaną gemcytabiną i blokadę punktu kontroli immunologicznej

Info

Publication number
PL3811949T3
PL3811949T3 PL19821941.2T PL19821941T PL3811949T3 PL 3811949 T3 PL3811949 T3 PL 3811949T3 PL 19821941 T PL19821941 T PL 19821941T PL 3811949 T3 PL3811949 T3 PL 3811949T3
Authority
PL
Poland
Prior art keywords
gemcitabine
immune checkpoint
liposome composition
checkpoint blockade
combined medicine
Prior art date
Application number
PL19821941.2T
Other languages
English (en)
Inventor
Takashi Komori
Tadaaki Ioroi
Takeshi Matsumoto
Yasuyuki Izumi
Original Assignee
Fujifilm Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corporation filed Critical Fujifilm Corporation
Publication of PL3811949T3 publication Critical patent/PL3811949T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL19821941.2T 2018-06-20 2019-06-20 Lek kombinowany zawierający kompozycję liposomową z kapsułkowaną gemcytabiną i blokadę punktu kontroli immunologicznej PL3811949T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2018116706 2018-06-20
JP2018211290 2018-11-09
JP2019092245 2019-05-15
PCT/JP2019/024499 WO2019244978A1 (ja) 2018-06-20 2019-06-20 ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬

Publications (1)

Publication Number Publication Date
PL3811949T3 true PL3811949T3 (pl) 2024-10-28

Family

ID=68983397

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19821941.2T PL3811949T3 (pl) 2018-06-20 2019-06-20 Lek kombinowany zawierający kompozycję liposomową z kapsułkowaną gemcytabiną i blokadę punktu kontroli immunologicznej

Country Status (12)

Country Link
US (1) US12201723B2 (pl)
EP (1) EP3811949B1 (pl)
JP (2) JP7364561B2 (pl)
CN (1) CN112334140A (pl)
AU (1) AU2019288048B2 (pl)
CA (1) CA3104084C (pl)
DK (1) DK3811949T3 (pl)
ES (1) ES2984147T3 (pl)
FI (1) FI3811949T3 (pl)
PL (1) PL3811949T3 (pl)
TW (3) TWI892261B (pl)
WO (1) WO2019244978A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2984147T3 (es) 2018-06-20 2024-10-29 Fujifilm Corp Medicamento combinado que comprende una composición liposómica de gemcitabina encapsulada y bloqueo de punto de control inmunitario
CN115551517A (zh) * 2020-04-03 2022-12-30 富士胶片株式会社 抗肿瘤剂
CN113288871B (zh) * 2021-05-28 2022-09-16 华中科技大学 用于调控表观遗传与免疫检查点的药物组合物脂质体制剂

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4970074A (en) 1987-06-29 1990-11-13 Abbott Laboratories Fluorophores for encapsulation into liposomes
US5328678A (en) 1987-11-04 1994-07-12 Vestar, Inc. Composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy
DE68901733T2 (de) 1988-03-04 1993-03-25 Takeda Chemical Industries Ltd Liposom-zusammensetzung.
JP2931981B2 (ja) 1988-03-04 1999-08-09 武田薬品工業株式会社 リポソーム製剤およびその製造法
US5049392A (en) 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
IS1685B (is) 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
CA2093381A1 (en) 1992-04-07 1993-10-08 Hideyuki Sawahara Liposome formulation and process for production thereof
JPH069374A (ja) 1992-04-07 1994-01-18 Banyu Pharmaceut Co Ltd リポソ−ム製剤およびその製造法
ATE164515T1 (de) 1993-11-05 1998-04-15 Amgen Inc Herstellung von liposomen und verfahren zur substanzverkapselung
US5540935A (en) 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
US6261597B1 (en) 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
US6132789A (en) 1995-12-15 2000-10-17 National Research Council Of Canada Archaeosomes, archaeosomes containing coenzyme Q10, and other types of liposomes containing coenzyme Q10 as adjuvants and as delivery vehicles
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
AU2003268087A1 (en) 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery
EP1585504A4 (en) 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
US20040265368A1 (en) 2003-04-02 2004-12-30 Lawrence Mayer Combination compositions of camptothecins and fluoropyrimidines
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
WO2005021012A1 (ja) 2003-08-29 2005-03-10 Terumo Kabushiki Kaisha ゲムシタビン封入薬剤担体
LT3173073T (lt) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
NZ551406A (en) * 2004-06-03 2010-03-26 Hoffmann La Roche Treatment of non small cell lung cancer with gemcitabine and erlotinib (an egfr kinase inhibitor)
CA2581133A1 (en) 2004-09-20 2006-03-30 British Columbia Cancer Agency Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
US20100292454A1 (en) 2005-06-22 2010-11-18 Yuji Mishina Neuronal regeneration promoting agent
WO2007005754A2 (en) 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
CA2631243A1 (en) 2005-12-08 2007-06-14 Wyeth Liposomal compositions
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
JP5080779B2 (ja) 2006-10-25 2012-11-21 テルモ株式会社 リポソーム製剤の製造方法
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
CN100496609C (zh) 2006-12-30 2009-06-10 上海艾力斯医药科技有限公司 一种稳定的脂质体组合物
CN101878229A (zh) 2007-09-28 2010-11-03 巴塞尔大学医院 用于治疗癌症的免疫脂质体
US8962614B2 (en) * 2008-04-17 2015-02-24 The Johns Hopkins University ON01910.Na enhances chemotherapeutic agent activity in drug-resistant tumors
US8231895B2 (en) 2008-05-22 2012-07-31 Universidade De Coimbra Targeted delivery to human diseases and disorders
CN101444485B (zh) 2008-12-25 2011-11-23 中国医药集团总公司四川抗菌素工业研究所 吉西他滨脂质体及其制备方法
PL387296A1 (pl) 2009-02-17 2010-08-30 Instytut Farmaceutyczny Sposób aktywnego zamykania amfifilowych substancji czynnych w strukturach liposomowych
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
KR20120086729A (ko) 2009-11-20 2012-08-03 클라비스 파마 에이에스에이 젬시타빈 유도체의 비경구적 제제
WO2011066684A1 (zh) 2009-12-03 2011-06-09 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
JP2013126953A (ja) 2010-03-31 2013-06-27 Terumo Corp リポソーム製剤の製造方法
CN101822669B (zh) 2010-04-23 2012-06-13 海南美兰史克制药有限公司 一种阿莫西林钠舒巴坦钠药物组合物脂质体注射剂
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
CN101926779A (zh) * 2010-08-19 2010-12-29 苏州特瑞药业有限公司 一种吉西他滨固体脂质纳米粒及其制备方法与用途
WO2012055020A1 (en) 2010-10-27 2012-05-03 Ontario Institute For Cancer Research Thermosensitive liposomes
BR112013024663A2 (pt) 2011-03-25 2016-12-20 Terumo Corp composição de lipossomas de liberação controlada de longa duração e método para produção da mesma
JP5853453B2 (ja) 2011-07-15 2016-02-09 コニカミノルタ株式会社 リポソームを製造する方法
US8987224B2 (en) 2011-08-05 2015-03-24 Baylor College Of Medicine MicroRNA-198 as a tumor suppressor in pancreatic cancer
CN104023793B (zh) 2011-10-31 2017-11-24 马林克罗特有限公司 用于治疗癌症的联合脂质体组合物
EP2604253A1 (en) 2011-12-13 2013-06-19 Otto Glatter Water-in-oil emulsions and methods for their preparation
CN108686203A (zh) 2012-04-04 2018-10-23 哈洛齐梅公司 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
CN102784107B (zh) 2012-05-17 2015-04-22 江苏豪森药业股份有限公司 一种吉西他滨或其盐脂质体及其制备方法和用途
CN102716089B (zh) 2012-06-29 2013-12-11 海南灵康制药有限公司 一种盐酸吉西他滨脂质体注射剂
US10188728B2 (en) 2012-12-12 2019-01-29 Temple University—Of the Commonwealth System of Higher Education Compositions and methods for treatment of cancer
US9968570B2 (en) 2013-01-14 2018-05-15 Chemo-Enhanced Llc Compositions and methods for treating cancer
EP4378461A3 (en) 2013-03-05 2024-09-11 The Regents of University of California Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
EA201690746A1 (ru) * 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
JP6263609B2 (ja) 2014-04-30 2018-01-17 富士フイルム株式会社 リポソーム組成物及びその製造方法
EP3138558B1 (en) 2014-04-30 2023-06-07 FUJIFILM Corporation Liposome composition and production method therefor
ES2909245T3 (es) 2014-04-30 2022-05-06 Fujifilm Corp Método para producir liposomas
WO2015166986A1 (ja) 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
WO2015176033A1 (en) * 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
WO2016172494A2 (en) * 2015-04-23 2016-10-27 The Johns Hopkins University Combination of immunotherapy with local chemotherapy for the treatment of malignancies
CA2990687A1 (en) * 2015-06-29 2017-01-05 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
CN105012966B (zh) * 2015-07-01 2018-11-02 南通厚元生物科技有限公司 吉西他滨-磷脂复合物的制备方法及其应用
DK3372232T3 (da) * 2015-11-02 2021-06-07 Fujifilm Corp Tumorterapeutisk middel omfattende gemcitabinliposomsammensætning og kit
EP3372223B1 (en) 2015-11-02 2024-04-17 FUJIFILM Corporation Liposome composition and method for producing same
CN106955354B (zh) * 2016-01-11 2020-06-19 中国科学院分子细胞科学卓越创新中心 用于肿瘤免疫治疗的联合用药物组合
WO2017192863A1 (en) 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
JP7041136B2 (ja) * 2016-10-12 2022-03-23 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｔｕｓｃ２免疫療法のための方法および組成物
KR20190092478A (ko) * 2016-12-05 2019-08-07 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
ES2984147T3 (es) 2018-06-20 2024-10-29 Fujifilm Corp Medicamento combinado que comprende una composición liposómica de gemcitabina encapsulada y bloqueo de punto de control inmunitario
US20230285295A1 (en) 2018-06-20 2023-09-14 Fujifilm Corporation Combined pharmaceutical formulation comprising gemcitabine-containing liposome composition and immune checkpoint inhibitor

Also Published As

Publication number Publication date
EP3811949B1 (en) 2024-07-03
TW202015703A (zh) 2020-05-01
WO2019244978A1 (ja) 2019-12-26
TWI882475B (zh) 2025-05-01
TW202402301A (zh) 2024-01-16
EP3811949A4 (en) 2021-08-04
FI3811949T3 (fi) 2024-09-13
JP2022116289A (ja) 2022-08-09
DK3811949T3 (da) 2024-10-07
AU2019288048B2 (en) 2022-08-11
TWI892261B (zh) 2025-08-01
TW202402302A (zh) 2024-01-16
AU2019288048A1 (en) 2021-01-14
JP7364561B2 (ja) 2023-10-18
EP3811949A1 (en) 2021-04-28
US12201723B2 (en) 2025-01-21
CA3104084C (en) 2023-08-01
CN112334140A (zh) 2021-02-05
TWI874322B (zh) 2025-03-01
ES2984147T3 (es) 2024-10-29
JPWO2019244978A1 (ja) 2021-06-03
CA3104084A1 (en) 2019-12-26
US20210106528A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
IL304717A (en) Antibody conjugates against cmet with drug and methods of using them
ZA202003833B (en) Conjugates and preparation and use thereof
ZA202000439B (en) Liposome compositions comprising weak acid drugs and uses thereof
SI3603620T1 (sl) Sestava liposomov in farmacevtska sestava
IL258212A (en) Combination therapy of bromodomain inhibitors and checkpoint blockade
ZA201802003B (en) Dual function proteins and pharmaceutical composition comprising same
ZA201801401B (en) Anti-dll3 antibody drug conjugates and methods of use
PT3443010T (pt) Novos anticorpos anti-sirpa e suas aplicações terapêuticas
SI3274321T1 (sl) Kanabidiolni izolat iz industrijske konoplje in njegova uporaba v farmacevtskih in/ali kozmetičnih pripravkih
SG11201801003YA (en) Tumor-specific anti-egfr antibody and application thereof
SG11201708624YA (en) Therapeutic antibodies and uses thereof
ZA201804223B (en) Bromodomain and extra-terminal protein inhibitor combination therapy
PL3811931T3 (pl) Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej
SMT202200135T1 (it) Terapia di combinazione con un inibitore di proteine a bromodomini ed extraterminali
GB201820659D0 (en) Novel compostions and their use in therapy
IL272050A (en) Synthetic proteins and their therapeutic uses
IL277007A (en) Therapeutic ANTI-SPLA2-GIB antibodies and their uses
PL3811949T3 (pl) Lek kombinowany zawierający kompozycję liposomową z kapsułkowaną gemcytabiną i blokadę punktu kontroli immunologicznej
IL292599A (en) tmem219 antibodies and medical uses thereof
PL3658122T3 (pl) Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
EP3647325A4 (en) PHARMACEUTICAL COMPOSITION OF PCSK-9 ANTIBODIES AND USES THEREOF
IL292646A (en) Pharmaceutical combination and its use
GB201519644D0 (en) Therapy and pharmaceutical composition
EP3263142A4 (en) Medical/cosmetic material and adhesion preventing material
GB201718320D0 (en) Therapeutic substances and their preparation